What is Axonics?
Founded in 2012 and headquartered in Irvine, California, Axonics Modulation Technologies is at the forefront of developing novel implantable neuromodulation technology. The company's focus is directed toward addressing several critical clinical indications through its advanced devices. Axonics operates within the burgeoning medical technology and healthcare innovation landscape, aiming to provide sophisticated solutions for patients requiring neuromodulation therapies.
How much funding has Axonics raised?
Axonics has raised a total of $251.7M across 5 funding rounds:
Series A
$32.6M
Series B
$38.5M
Series C
$20.5M
Series D
$40.1M
Stock Offering
$120M
Series A (2014): $32.6M with participation from Edmond de Rothschild Investment Partners (EdRIP), Legend Capital, and Neomed Management
Series B (2015): $38.5M led by Legend Capital, Neomed Management, Advent Life Sciences, Andera Partners, Cormorant Asset Management, The Alfred E. Mann Foundation, and Edmond de Rothschild Investment Partners
Series C (2017): $20.5M supported by Gilde Healthcare, Cormorant Asset Management, and CICA, Inc
Series D (2018): $40.1M featuring Gilde Healthcare, Longitude Capital, and Silicon Valley Bank
Stock Issuance/Offering (2018): $120M, investors not publicly disclosed
Key Investors in Axonics
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across Venture & Growth, Private Equity in Healthcare, and Private Equity in Climate Solutions. They focus on businesses enabling better care at lower costs and addressing planetary challenges.
Longitude Capital
Longitude Capital is a venture capital firm dedicated to the healthcare sector, investing in biotechnology, medical technology, and health solutions companies with a focus on improving patient care.
Silicon Valley Bank
SVB Financial Group provides a comprehensive suite of financial services including commercial and private banking, asset management, and investment services, primarily serving technology and innovation-focused companies.
What's next for Axonics?
The recent major strategic investment signals a pivotal phase for Axonics, likely enabling the company to accelerate its product development pipeline, expand its market reach, and further scale its operations. This capital infusion is expected to support the company's ongoing efforts to bring its innovative implantable neuromodulation solutions to a wider patient population, reinforcing its trajectory as a key player in the medical device industry. The company's sustained access to significant financing indicates strong investor confidence in its technological advancements and market strategy.
See full Axonics company page
